|
| Press Releases |
|
 |
|
| Friday, July 25, 2025 |
|
|
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million |
| Everest Medicines (HKEX 1952.HK, Everest or the " Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the "Sellers"), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue. more info >> |
|
| Friday, July 4, 2025 |
|
|
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation |
| Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company's progress in building a fully integrated and independently operated mRNA platform and highlighted significant breakthroughs across several pipeline programs in cancer and autoimmune diseases. more info >> |
|
| Thursday, June 12, 2025 |
|
|
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances |
| At the 62nd Congress of the European Renal Association (ERA 2025), Everest Medicines presented new results findings on both NEFECON(budesonide delayed release capsules), the world's first and only approved therapy that directly targets the underlying cause of IgA nephropathy (IgAN), and EVER001, a next-generation covalent reversible BTK inhibitor. more info >> |
|
| Monday, June 9, 2025 |
|
|
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025 |
| At the 62nd European Renal Association Congress (ERA 2025), Everest Medicines unveiled new clinical data on EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, in patients with primary membranous nephropathy (pMN). more info >> |
|
| Wednesday, May 7, 2025 |
|
|
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China |
| Everest Medicines (HKEX: 1952.HK) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA). more info >> |
|
| Tuesday, April 22, 2025 |
|
|
Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the 'Stock Exchange') has approved the Company's application to remove the "B" marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange. more info >> |
|
| Friday, March 7, 2025 |
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation |
| Everest Medicines' stock (1952.HK) surged today, opening higher and maintaining strong momentum throughout the trading day. By market close, the stock had risen 20.12% to HK$60.6, bringing the company's total market capitalization to HK$19.791 billion. more info >> |
|
| Wednesday, February 19, 2025 |
|
|
Goldman Sachs Raises Everest Medicines' Target Price to HK$48.32 on Stronger Commercial and R&D Outlook |
| Goldman Sachs' latest report on China's biotechnology sector highlights Everest Medicines (1952.HK) as a company on track to achieve EBITDA break-even by the end of 2025. This outlook is driven by the accelerated commercialization of Nefecon(R), which was recently included in China's National Reimbursement Drug List (NRDL). more info >> |
|
| Thursday, January 2, 2025 |
|
|
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy |
| Everest Medicines (HKEX 1952.HK, Everest , or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that with the official implementation of the latest update of the National Reimbursement Drug List ('NRDL') on January 1, 2025, NEFECON will apply the NRDL pricing, which will benefit more IgA nephropathy (IgAN) patients. more info >> |
|
| Wednesday, December 18, 2024 |
|
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription for VELSIPITY(R) has been written at Foshan Fosun Chancheng Hospital in Guangdong, under the "Hong Kong and Macau Medicine and Equipment Connect" policy, which marks the official beginning of this new therapy benefiting patients in mainland China. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Theinvestmedia.com Offers Exclusive Brokerage Account Opening Offers and In-Depth Tutorials, Empowering Investors with Precise Decision-Making
Jul 26, 2025 08:00 HKT/SGT
|
|
|
maxWin Receives Honesty Award 2025, Setting New Standards for Integrity in Online Gaming 
Jul 25, 2025 19:00 HKT/SGT
|
|
|
OMS Energy Recorded Significant Profits Growth in 2025FY, Roth Capital Rating it "Buy" with a Potential 40% Upside TP
Jul 25, 2025 17:18 HKT/SGT
|
|
|
CWE held 'Lancang Mekong Green Course' Open Day to celebrate the 10th anniversary of the Nam Ngiep 2 Hydropower Station
Jul 25, 2025 16:25 HKT/SGT
|
|
|
Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics
Jul 25, 2025 16:00 JST
|
|
|
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
Jul 25, 2025 13:31 JST
|
|
|
Ultraman Omega joins the battlefield alongside beloved Ultraman Arc in Tsuburaya Production's new Starter Deck 03 'Ω to the Future' and Booster Pack 4 'Gleam of Eternal Hope'
Jul 25, 2025 12:25 HKT/SGT
|
|
|
Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China
Jul 25, 2025 10:52 HKT/SGT
|
|
|
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million
Jul 25, 2025 10:01 HKT/SGT
|
|
|
International Land Alliance Announces Tiny Home Offerings at Cabo Oasis Development
Jul 24, 2025 22:04 HKT/SGT
|
|
|
HKTDC Research Report: Exploring Opportunities in Hong Kong's Proprietary Chinese Medicine Industry
Jul 24, 2025 17:43 HKT/SGT
|
|
|
ONERHT Foundation's 8th GAIL Forum held on 22 July 2025, Champions Green Leadership Across ASEAN
Jul 24, 2025 14:00 HKT/SGT
|
|
|
Quantum Solutions Announces Strategic Bitcoin Treasury Initiative
Jul 24, 2025 13:51 HKT/SGT
|
|
|
Fujitsu and Nagoya University develop simulation tech to combat transportation gaps
Jul 24, 2025 12:30 JST
|
|
|
Honda Reveals Details of its Support of the World Athletics Championships Tokyo 25
Jul 24, 2025 12:03 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
